UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy

Molecular cancer therapeutics, 2012-02, Vol.11 (2), p.475-484

2012

Volltextzugriff (PDF)

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non―Small Cell Lung Cancer

Clinical cancer research, 2012-09, Vol.18 (18), p.4973-4985

2012

Volltextzugriff (PDF)

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism

Molecular cancer research, 2014-07, Vol.12 (7), p.1042-1054

2014

Volltextzugriff (PDF)

Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer

PloS one, 2011-11, Vol.6 (11), p.e27018

2011

Volltextzugriff (PDF)

The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus

PloS one, 2015-05, Vol.10 (5), p.e0127361

2015

Volltextzugriff (PDF)

Art-based psychosocial interventions in Japan: cross-cultural encounters

International journal of art therapy, 2021-10, Vol.26 (4), p.161-169

2021

Volltextzugriff (PDF)

The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells

Free radical biology & medicine, 2012-05, Vol.52 (10), p.2142-2150

2012

Volltextzugriff (PDF)

Immobilization and cleavage of DNA at cationic, self-assembled monolayers containing C60 on gold

Chemical communications (Cambridge, England), 1997 (16), p.1507-1508

1997

Volltextzugriff (PDF)

Determination of Thiols by Capillary Electrophoresis with Amperometric Detection at a Coenzyme Pyrroloquinoline Quinone Modified Electrode

Analytical chemistry (Washington), 2002-03, Vol.74 (6), p.1349-1354

2002

Volltextzugriff (PDF)

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors

Toxicology and applied pharmacology, 2013-12, Vol.273 (2), p.401-409

2013

Volltextzugriff (PDF)

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

BMC cancer, 2013-03, Vol.13 (1), p.152-152, Article 152

2013

Volltextzugriff (PDF)

Electrochemical Detection of Thiols with a Coenzyme Pyrroloquinoline Quinone Modified Electrode

Analytical chemistry (Washington), 2000-12, Vol.72 (23), p.5755-5760

2000

Volltextzugriff (PDF)

HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2422-2432

2015

Volltextzugriff (PDF)

Abstract 1619: Hsp90 inhibitor drug conjugates (HDCs): Construct design and preliminary evaluation

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1619-1619

2014

Volltextzugriff (PDF)

Abstract 4409: STA-12-8666: a first-in-class HSP90 inhibitor drug conjugate (HDC) designed to selectively deliver chemotherapy to tumors

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4409-4409

2015

Volltextzugriff (PDF)

Potent anti-inflammatory activity of a novel of class Hsp90 inhibitors for multiple sclerosis (51.1)

The Journal of immunology (1950), 2012-05, Vol.188 (1_Supplement), p.51-51.1

2012

Volltextzugriff (PDF)

Abstract 2509: Hsp90-inhibitor drug conjugates (HDC): Novel tumor-selective drug delivery platform with unprecedented anticancer activity

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2509-2509

2014

Volltextzugriff (PDF)

Abstract 1282: Phase I evaluation of STA-1474, a pro-drug of the novel HSP90 inhibitor STA-9090, in dogs with spontaneous cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.1282-1282

2011

Volltextzugriff (PDF)

Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3086-3086

2012

Volltextzugriff (PDF)

Abstract C168: Cancer-selective mitochondrial copper transport by elesclomol results in potent single agent efficacy in multiple tumor types

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.C168-C168

2011

Volltextzugriff (PDF)

Abstract C212: A critical role for the tissue distribution profile in heat shock protein (Hsp) 90 inhibitor-induced ocular toxicity in rats

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.C212-C212

2011

Volltextzugriff (PDF)

Abstract B105: Ganetespib, a unique resorcinolic Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile in preclinical models

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.B105-B105

2011

Volltextzugriff (PDF)

Effects of PAC (personal attitude construct) analysis in counseling

Shinrigaku kenkyū, 1998-10, Vol.69 (4), p.295-303

Inoue, T

1998

Volltextzugriff (PDF)

Ganetespib (STA-9090), a Non-Geldanamycin HSP90 Inhibitor, has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer

Clinical cancer research, 2012-07, Vol.18 (18), p.4973-4985

2012

Volltextzugriff (PDF)

Abstract C11: The oxidative stress inducer elesclomol requires copper chelation for its anticancer activity

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.C11-C11

2009

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(68)
Dissertationen
(1)

Sprache

Englisch
(61)
Japanisch
(23)

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Life Sciences & Biomedicine
(22)
Humans
(18)
Female
(16)
Male
(13)
Physical Sciences
(12)
Animals
(10)
Chemistry
(9)
Adult
(8)
Biological And Medical Sciences
(8)
Hsp90 Heat-Shock Proteins - Antagonists & Inhibitors
(8)
Middle Aged
(8)
Aged
(7)
Biochemistry & Molecular Biology
(7)
Chemistry, Analytical
(7)
Medical Sciences
(6)
Neoplasms - Drug Therapy
(6)
Oncology
(6)
Cell Line, Tumor
(5)
Hsp90 Heat-Shock Proteins - Metabolism
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non―Small Cell Lung Cancer

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism

Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer

The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus

Art-based psychosocial interventions in Japan: cross-cultural encounters

The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells

Immobilization and cleavage of DNA at cationic, self-assembled monolayers containing C60 on gold

Determination of Thiols by Capillary Electrophoresis with Amperometric Detection at a Coenzyme Pyrroloquinoline Quinone Modified Electrode

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

Electrochemical Detection of Thiols with a Coenzyme Pyrroloquinoline Quinone Modified Electrode

HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors

Abstract 1619: Hsp90 inhibitor drug conjugates (HDCs): Construct design and preliminary evaluation

Abstract 4409: STA-12-8666: a first-in-class HSP90 inhibitor drug conjugate (HDC) designed to selectively deliver chemotherapy to tumors

Potent anti-inflammatory activity of a novel of class Hsp90 inhibitors for multiple sclerosis (51.1)

Abstract 2509: Hsp90-inhibitor drug conjugates (HDC): Novel tumor-selective drug delivery platform with unprecedented anticancer activity

Abstract 1282: Phase I evaluation of STA-1474, a pro-drug of the novel HSP90 inhibitor STA-9090, in dogs with spontaneous cancer

Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors

Abstract C168: Cancer-selective mitochondrial copper transport by elesclomol results in potent single agent efficacy in multiple tumor types

Abstract C212: A critical role for the tissue distribution profile in heat shock protein (Hsp) 90 inhibitor-induced ocular toxicity in rats

Abstract B105: Ganetespib, a unique resorcinolic Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile in preclinical models

Effects of PAC (personal attitude construct) analysis in counseling

Ganetespib (STA-9090), a Non-Geldanamycin HSP90 Inhibitor, has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer

Abstract C11: The oxidative stress inducer elesclomol requires copper chelation for its anticancer activity

Suchergebnisse filtern